This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
Ultrasound Renal Denervation: Interdisciplinary Approach to Better Patient Outcomes
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Intracranial Activity of ROS1 TKIs
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Clinical Challenges With Triple-Class or Penta-Refractory MM
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Integrating Bispecific Antibodies Into Clinical Practice
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video